Sofosbuvir Based Regimens in the Treatment of Chronic Hepatitis C with Compensated Liver Cirrhosis in Community Care Setting

Table 4

SVR 12 rates in patients receiving SOF/VEL by population subgroup.

Response	SVR 12 Rate	Univariate Analysis; p-value	Multivariate Analysis; p-value
Overall	23/25 (92.0)
Age group		1.000	NA
< 65	17/19 (89.5)
≥ 65	6/6 (100)
Sex		0.520	NA
Male	14/16 (87.5)
Female	9/9 (100)
BMI (Kg/m^2)		1.000	NA
< 30	12/13 (92.3)
≥ 30	11/12 (91.7)
HCV Genotype		0.789	NA
1a	12/14 (85.7)
1b	6/6 (100)
2	1/1 (100)
3	1/1 (100)
4	3/3 (100)
HCV RNA (IU/mL)		1.000	NA
< 800,000	5/5 (100)
≥ 800,000	18/20 (90.0)
Prior treatment		1.000	NA
Naïve	15/16 (93.8)
Experienced	8/9 (88.9)
Comorbidities
Diabetes	10/10 (100)	0.500	NA
Hypertension	13/14 (92.9)	1.000	NA
CAD	3/3 (100)	1.000	NA
Kidney disease	1/1 (100)	1.000	NA
Chronic anemia	2/3 (66.7)	0.230	NA
HIV Seropositive	2/3 (66.7)	0.230	NA
MELD Score		0.487	NA
< 10	11/11 (100)
≥ 10	12/14 (85.7)
ALT (IU/L)		1.000	NA
< 40	4/4 (100)
≥ 40	19/21 (90.5)

Data presented as number/total number (percent).
BMI, body mass index; HCV, hepatitis C virus; RNA, ribonucleic acid; APRI, AST-to-platelet ratio index; MELD, model for end-stage liver disease; and ALT, alanine transaminase.